Form 8-K - Current report:
SEC Accession No. 0001193125-25-238989
Filing Date
2025-10-14
Accepted
2025-10-14 16:02:55
Documents
13
Period of Report
2025-10-10
Items
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
Item 7.01: Regulation FD Disclosure
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K fate-20251010.htm   iXBRL 8-K 64735
2 EX-10.1 fate-ex10_1.htm EX-10.1 43970
3 EX-99.1 fate-ex99_1.htm EX-99.1 20188
4 GRAPHIC img158830969_0.jpg GRAPHIC 20472
  Complete submission text file 0001193125-25-238989.txt   279928

Data Files

Seq Description Document Type Size
5 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT fate-20251010.xsd EX-101.SCH 25073
15 EXTRACTED XBRL INSTANCE DOCUMENT fate-20251010_htm.xml XML 4738
Mailing Address 12278 SCRIPPS SUMMIT DRIVE SAN DIEGO CA 92131
Business Address 12278 SCRIPPS SUMMIT DRIVE SAN DIEGO CA 92131 858.875.1803
FATE THERAPEUTICS INC (Filer) CIK: 0001434316 (see all company filings)

EIN.: 651311552 | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-36076 | Film No.: 251391711
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)